RIPK3 and neoplasm: The median survival for the mice from both the RapaCas9 and HSV-TK groups was 15 days after rechallenge, whereas all mice from the group subjected to the RIPK3 system survived until the termination of the experiment, and no tumor growth was observed (Figure 3F).